BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 28484168)

  • 1. [Current diagnosis and treatment for acute myeloid leukemia].
    Kobayashi Y
    Rinsho Ketsueki; 2017; 58(4):364-372. PubMed ID: 28484168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute myeloid Leukemia].
    Braess J
    Dtsch Med Wochenschr; 2016 Nov; 141(24):1748-1751. PubMed ID: 27835920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy of acute myeloid leukemia.
    Carneiro BA; Altman JK; Kaplan JB; Ossenkoppele G; Swords R; Platanias LC; Giles FJ
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):399-413. PubMed ID: 25623136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia.
    de Leeuw DC; Verhagen HJ; Denkers F; Kavelaars FG; Valk PJ; Schuurhuis GJ; Ossenkoppele GJ; Smit L
    Leukemia; 2016 Mar; 30(3):742-6. PubMed ID: 26108690
    [No Abstract]   [Full Text] [Related]  

  • 7. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
    Bullinger L; Döhner K; Döhner H
    J Clin Oncol; 2017 Mar; 35(9):934-946. PubMed ID: 28297624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute leukemia in adults].
    Eigendorff E; Hochhaus A
    Pathologe; 2015 Sep; 36(5):503-17; quiz 518-9. PubMed ID: 26314268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gene mutations in acute myeloid leukemia].
    Yamaguchi H
    Rinsho Ketsueki; 2016; 57(12):2535-2542. PubMed ID: 28090023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
    Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
    Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia.
    Weng H; Lal K; Yang FF; Chen J
    Cancer Genet; 2015 May; 208(5):225-9. PubMed ID: 25686674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of acute myeloblastic leukemia. 79 cases treated by cytosine-rubidomycin combination].
    Brun B; Rochant H; Gluckman E; Reyes F; Dreyfus B
    Nouv Presse Med; 1974 Feb; 3(6):291-4. PubMed ID: 4522835
    [No Abstract]   [Full Text] [Related]  

  • 19. [Advances in targeted therapy for childhood acute myeloid leukemia].
    Wang NN; Ye QD
    Zhongguo Dang Dai Er Ke Za Zhi; 2017 Jul; 19(7):832-836. PubMed ID: 28697841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
    Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
    Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.